Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Purpose: To report the efficacy and safety of intravitreal ranibizumab for neovascular age-
related macular degeneration (nAMD) in real-world practice. Methods: Metaanalysis of∼ …

Purpose To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF)
therapy for treatment-naïve eyes with neovascular age-related macular degeneration …

To assess predictors of treatment response in neovascular age‐related macular
degeneration (AMD) in an attempt to develop a patient‐centric treatment algorithm. We …

Purpose To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for
eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical …

Background/objectives To investigate the association between optical coherence
tomography (OCT) markers of lesion activity and changes in visual acuity (VA) during anti …

Purpose To present the treatment patterns, disease activity, and visual outcomes of eyes in
the maintenance phase of a treat-and-extend regimen for neovascular age-related macular …

The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the
treatment of neovascular age‐related macular degeneration (nAMD) since the pivotal Phase …

Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related
macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs) …

Purpose To compare 5-year real-world outcomes of eyes with classic and occult choroidal
neovascularization (CNV) treated with anti–vascular endothelial growth factor (anti-VEGF) …